First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.

Wolfgang KnaufGerrit DingeldeinRudolf SchlagManfred WelslauThomas MoehlerTobias TerzerSarah WalterChristina HabermehlChristina KunzHartmut GoldschmidtMarc-Steffen Raabnull null

Published in: European journal of haematology (2020)

Bendamustine/prednisone/bortezomib may serve as a first-line regimen for transplant-ineligible elderly MM patients in particular for patients with renal impairment requiring a fast and durable renal response.

Keyphrases

multiple myeloma
newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
clinical trial
stem cells
patient reported